Fenofibrate and diabetic retinopathy

The Lancet

Volumn 371, Issue 9614, 2008, Pages 721-

  Liew, Gerald ^a   Gillies, Mark ^a   Wang, Jie Jin ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 39649098717     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60332-3     Document Type: Letter

References (5)

1. Keech A., Mitchell P., Summanen P., et al., for the FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
2. Klein R., Klein B., Moss S., and Wang Q. Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population. Arch Ophthalmol 112 (1994) 92-98
3. Wong T., Klein R., Couper D., et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 358 (2001) 1134-1140
4. Sen K., Misra A., Kumar A., and Pandey R. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 56 (2002) 1-11
5. Gupta A., Gupta V., Thapar S., and Bhansali A. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 137 (2004) 675-682